Key result
Post-AMI beta-blocker use is linked to a ~28% lower risk of death.
Why the study?
Observational studies of beta-blocker effects on all-cause mortality after AMI have tended to overestimate treatment effectiveness.
Does beta-blocker use reduce all-cause mortality in patients surviving 90 days post-AMI?
Population
9,939 subjects who survived 90 days after first AMI in the UK GPRD 2002-2004
Comparison
Post-AMI beta-blocker use vs non-use
Design
Population-based cohort study with traditional regression and marginal structural models
Follow-up
9 months
Authors
Loading...
Observational estimates support beta-blocker use post-AMI; leaves open confirmation by RCTs using marginal structural models.
Cohort (n=9,939)
Does beta-blocker use reduce all-cause mortality in patients surviving 90 days post-AMI?
Relative Risk: 0.72 (95% CI 0.61–0.84)
Marginal structural models (IPTW) provide more conservative and likely more accurate estimates of beta-blocker effectiveness post-AMI compared to traditional regression models, aligning better with RCT data.
Delaney et al. (2008) conducted a cohort in acute myocardial infarction (AMI) (n=9,939). beta-blocker use vs. no beta-blocker use was evaluated on death (RR 0.72, 95% CI 0.61-0.84). Post-AMI beta-blocker use was associated with a reduced risk of death (RR 0.72; 95% CI 0.61-0.84) using a marginal structural model, correcting exaggerated effects from traditional models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: